About Histone acetyltransferase type B catalytic subunit
Histone acetyltransferase type B catalytic subunit (HAT1) is a protein
from Homo sapiens identified by UniProt accession
O14929, 419 residues long.
MolForge cross-references it against 0 known binders and
111 disease associations.
Target properties
| Protein name | Histone acetyltransferase type B catalytic subunit |
| UniProt accession | O14929 |
| Gene | HAT1 |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (111)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- breast adenocarcinoma · score 0.22
- type 2 diabetes mellitus · score 0.16
- self reported educational attainment · score 0.11
- waist circumference · score 0.11
- mathematical ability · score 0.11
- Abnormality of refraction · score 0.09
- intelligence · score 0.09
- schizophrenia · score 0.09
- reaction time measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14929-F1 | alphafold | PREDICTED | 92.80 | — |
Amino-acid sequence (419 residues)
MAGFGAMEKF LVEYKSAVEK KLAEYKCNTN TAIELKLVRF PEDLENDIRT FFPEYTHQLF GDDETAFGYK GLKILLYYIA GSLSTMFRVE YASKVDENFD CVEADDVEGK IRQIIPPGFC TNTNDFLSLL EKEVDFKPFG TLLHTYSVLS PTGGENFTFQ IYKADMTCRG FREYHERLQT FLMWFIETAS FIDVDDERWH YFLVFEKYNK DGATLFATVG YMTVYNYYVY PDKTRPRVSQ MLILTPFQGQ GHGAQLLETV HRYYTEFPTV LDITAEDPSK SYVKLRDFVL VKLCQDLPCF SREKLMQGFN EDMVIEAQQK FKINKQHARR VYEILRLLVT DMSDAEQYRS YRLDIKRRLI SPYKKKQRDL AKMRKCLRPE ELTNQMNQIE ISMQHEQLEE SFQELVEDYR RVIERLAQE
Explore Histone acetyltransferase type B catalytic subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets